Enasidenib
Enasidenib is an orally available, selective, potent, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). Neomorphic mutations in IDH2 are frequently found in both hematologic malignancies and solid tumors and lead to the production of the oncometabolite (R)-2-hydroxyglutarate. Inc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Kapitel/Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
02 August 2018
|
| In: |
Small molecules in hematology
Year: 2018, Pages: 187-197 |
| DOI: | 10.1007/978-3-319-91439-8_9 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/978-3-319-91439-8_9
|
| Verfasserangaben: | Alwin Krämer, Tilmann Bochtler |
| Zusammenfassung: | Enasidenib is an orally available, selective, potent, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). Neomorphic mutations in IDH2 are frequently found in both hematologic malignancies and solid tumors and lead to the production of the oncometabolite (R)-2-hydroxyglutarate. Increased levels of (R)-2-hydroxyglutarate cause histone and DNA hypermethylation associated with blocked differentiation and tumorigenesis. In PDX mice transplanted with human IDH2-mutant acute myeloid leukemia cells, enasidenib treatment led to normalization of (R)-2-hydroxyglutarate serum levels, differentiation of leukemic blasts and increased survival. Early clinical data in patients with relapsed/refractory IDH2-mutant acute myeloid leukemia show that enasidenib is well tolerated and induces durable complete remissions as a single agent in about 20% of cases. One notable drug-related adverse effect is differentiation syndrome. On the basis of these results the compound has recently been approved for the treatment of relapsed/refractory IDH2-mutant acute myeloid leukemia in the USA. Although no data are available yet, clinical trials on the treatment of patients with several types of IDH2-mutant solid tumors including gliomas, chondrosarcomas and cholangiocarcinomas are currently being performed. |
|---|---|
| Beschreibung: | Gesehen am 28.10.2019 |
| Beschreibung: | Online Resource |
| ISBN: | 9783319914398 |
| DOI: | 10.1007/978-3-319-91439-8_9 |